Arrowhead Pharmaceuticals vs Oruka Therapeutics
Arrowhead Pharmaceuticals (ARWR), health care, and Oruka Therapeutics (ORKA), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Oruka Therapeutics is worth $6.5B on the stock market and Arrowhead Pharmaceuticals $6.1B: Oruka Therapeutics is valued at 7% more. Over the past year Arrowhead Pharmaceuticals's share price has moved +9.24% and Oruka Therapeutics's +262%.
Key facts
- Arrowhead Pharmaceuticals market value
- $6.1B
- Oruka Therapeutics market value
- $6.5B
- Arrowhead Pharmaceuticals revenue
- $829.4MFY to 2025-09-30
- Superinvestors holding both
- 0
Market values as of .
| Measure | Arrowhead Pharmaceuticals | Oruka Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-09-30 | 2025-12-31 |
| Size | ||
| Market cap | $6.1Blower | $6.5Bhigher |
| Revenue | $829.4M | — |
| Earnings | -$1.6Mhigher | -$105.4Mlower |
| Employees | 711higher | 68lower |
| Total assets | $1.4Bhigher | $488.6Mlower |
| Valuation | ||
| P/E | — | — |
| P/S | 7.3 | — |
| P/B | 121higher | 5.4lower |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 11.9% | — |
| Balance sheet | ||
| Net assets | $466.1Mlower | $471.9Mhigher |
| Total liabilities | $881.9Mhigher | $16.7Mlower |
| Total debt | — | — |
| Cash on hand | $226.5Mhigher | $46.9Mlower |
| Price change | ||
| Today | -2.76%higher | -2.94%lower |
| 1 year | +9.24%lower | +262%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Arrowhead Pharmaceuticals only (2)
Oruka Therapeutics only (3)
- Peter Kolchinsky1.3%
- Andreas Halvorsen0.4%
- Polen Capital team<0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns ARWR · Who owns ORKA
More on Arrowhead Pharmaceuticals
Further comparisons
Arrowhead Pharmaceuticals against its closest peers
Oruka Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Arrowhead Pharmaceuticals or Oruka Therapeutics?
By market value, Oruka Therapeutics is the larger: $6.5B against $6.1B for Arrowhead Pharmaceuticals.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Arrowhead Pharmaceuticals and Oruka Therapeutics?
None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Arrowhead Pharmaceuticals and 3 hold Oruka Therapeutics.
Cite this page
Funkfolio, “Arrowhead Pharmaceuticals vs Oruka Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/arwr-vs-orka
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.